6
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Superior vena cava syndrome as a paraneoplastic manifestation of soft tissue sarcoma

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction Superior vena cava (SVC) syndrome occurs because of SVC obstruction; the obstruction can be due to external pressure on the vein or to an internal obstruction with thrombus formation in the vein.1, 2 With the growing use of intravenous catheters and other devices, benign etiologies of SVC syndrome have become more common.3, 4 Most etiologies of SVC syndrome are malignant with the most common being lung cancer, lymphomas (Hodgkin's and non-Hodgkin), and breast cancer.1, 2 Other benign causes include thyroid goiter, aortic aneurysm, tuberculosis and thymoma. 2 In this article, we present the case of a woman with a malignant cause of SVC thrombosis but without any mass identified in the mediastinum. Case report A 46-year-old woman was admitted into hospital because of dyspnea, right arm pain and dysphagia. Forty-five days before admission she had developed pain in the right trunk and right scapula. Fifteen days prior to admission, she developed periorbital edema that slowly progressed to the entire face (Figure 1), neck, upper right extremity, upper trunk and both breasts. She also complained of erythema and pruritus of her forehead, cheeks and skin of the upper trunk during this period. She had evolved with progressive dyspnea and dysphagia for one week preceding admission. She had no history of fever, weight loss or night sweating. In the physical examination, the patient was not febrile and her respiratory rate was 22 breaths per minute. Beside the edema, collateral vessels were visible in her upper chest. Figure 1 Face edema. A chest X-ray was normal. Color Doppler ultrasonography of the upper extremity veins revealed normal flow in the left jugular vein, non-obstructive echogenic thrombosis in the right jugular vein and obstructive thrombosis in the right subclavian vein. A spiral chest computed tomography scan with contrast enhancement revealed bilateral pleural effusion in particular on the right side; thrombosis was identified in the superior vena cava that extended to the left subclavian vein. Moreover, bilateral lung nodules were found compatible with metastasis, as was a mass in the right rotator cuff muscles with scapular bone destruction (Figure 2). Laboratory data of the patient are shown in Table 1. Figure 2 (A) Right rotator cuff mass (arrow) with scapular bone destruction. (B) Superior vena cava thrombosis (arrow head). (C) Pulmonary nodules. Table 1 Laboratory tests of the patient. Table 1 Variable Value Reference value Variable Value Reference value WBC (/μL) 8.1 × 103 4–10 × 103 TSH (IU/mL) 2.8 0.34–4.25 Hemoglobin (g/dL) 13 12.0–15.8 PT (S) 15 12–14 Platelet (/L) 306 × 109 165–415 × 109 PTT (S) 27 25–35 Cr (mg/dL) 1.0 Female 0.5–0.9 Sodium (meq/L) 133 135–145 Calcium (mg/dL) 9.0 8.5–10.2 Potassium (meq/L) 4.0 3.5–5.5 Alp (U/L) Normal Blood sugar (mg/dL) 87 70–110 ESR (mm/h) 25 0–20 LDH (U/L) 799 (Upper-limit = 480) CRP (mg/L) 36 <10 WBC, White blood cell count; Cr, Creatinine; Alp, Alkaline phosphatase; ESR, Erythrocyte sedimentation rate; CRP, C-reactive protein; TSH, Thyroid-stimulating hormone; PT, Prothrombin time; PTT, Partial thromboplastin time; LDH, Lactate dehydrogenase. Enoxaparin therapy was initiated and core needle biopsy of the mass was performed. The pathology exam identified sarcoma which was confirmed by immunohistochemistry staining (Figure 3). Fifteen days after starting chemotherapy, her upper trunk edema was reduced significantly but the patient suddenly developed dyspnea and expired before any diagnostic procedure was performed. Pulmonary embolism was the most probable cause in spite of the regular enoxaparin injections from the time of her admission. Figure 3 Histology and immunohistochemistry of the tumor. (A) Wright's and Giemsa staining. (B) CD34 staining. (C) Smooth muscle actin (SMA). (D) Desmin. (E) Ki-67 protein. Discussion Intraluminal obstruction of the SVC may have benign or malignant causes. Long-term indwelling catheters, pacemaker wires and other intraluminal devices are common benign causes of SVC thrombosis.1, 2, 3, 4 Because the contrast enhanced computed tomography scan of our patient did not identify any mass, it follows that the SVC syndrome was a paraneoplastic syndrome. Santra et al. reported paraneoplastic thrombus formation in SVC due to lung cancer. 5 Moreover, paraneoplastic causes of SVC syndrome due to thrombosis have been reported in association with renal cell carcinoma, 6 ovarian cancer 7 and Richter syndrome. 8 Obstruction of the SVC can also be due to intraluminal metastasis without thrombus formation. Takayoshi et al. reported a case of adenosquamous carcinoma of the duodenum with intraluminal SVC metastasis. 9 Furthermore, invasive thymoma 10 and prostate cancer 11 with intravenous metastasis have been reported. Thus, when a cancer is diagnosed but without any mass being identified in the upper mediastinum, paraneoplastic thrombosis is the most probable cause of SVC syndrome as in our case unless anticoagulation was ineffective for which a biopsy of the intravenous lesion is necessary. In addition, when a cause for SVC syndrome is not found, a biopsy is necessary for differential diagnosis, which includes metastasis, thrombosis, granuloma, fungal lesion, etc. Most common symptoms are shortness of breath, cough, and swelling of face, neck, upper chest and extremities. Swelling may result in stridor, dysphagia and hoarseness. Chronic SVC syndrome causes distention of collateral veins, which may be seen in the upper chest. 12 Pleural effusion is observed in 60% of cases. 2 The signs and symptoms of our patient were compatible with chronic SVC syndrome. Management includes chemotherapy or radiotherapy for malignant causes when a mass is the cause. Stent placement is increasingly being used to ameliorate compression of the vessel resulting from malignant causes.1, 2 Occasionally bypass surgery is performed. 13 Other nonspecific methods include head elevation, mild diuresis and corticosteroids to decrease swelling and dyspnea. When thrombosis is the cause of SVC syndrome, thrombolysis 1 and/or anticoagulation1, 2, 3, 4, 5 may be indicated. Our patient received anticoagulation and chemotherapy. Acute dyspnea and death were most probably due to pulmonary emboli. In the study of Paolo et al. of 842 patients with deep vein thrombosis, 181 were known to have cancer and recurrent thromboembolism occurred in 20.7%, most commonly during the first month of anticoagulation as in our patient. 14 Conclusion We reported an uncommon cause of SVC syndrome due to paraneoplastic SVC thrombosis, with a poor outcome, most probably due to pulmonary embolism during anticoagulation. Physicians should be alert during the management of SVC syndrome, in particular when the cause is malignant. Conflicts of interest The authors declare no conflicts of interest.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: not found
          • Article: not found

          Clinical practice. Superior vena cava syndrome with malignant causes.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Superior vena cava syndrome: A medical emergency?

            Superior vena cava (SVC) syndrome was originally described as being secondary to an infection. Currently, it is almost exclusively secondary to malignancy. A case of SVC syndrome presenting with dyspnea, facial swelling, neck distension and cough developed over a period of 10 days is reported. The approach included imaging studies and tissue diagnosis. Computed tomography scan of the chest revealed a lobulated mass on the right upper chest invading the mediastinum, and cytology obtained from bronchoscopy revealed squamous cell carcinoma. The etiology, diagnosis and treatment modalities of the SVC syndrome are discussed.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Complications of Vascular Access: Superior Vena Cava Syndrome.

              Stenosis or occlusion of central veins in hemodialysis patients is common, especially with previous intravascular catheter or device use. Superior vena cava (SVC) obstruction is emerging as a frequent chronic complication of central vein cannulation that not only jeopardizes the availability of vascular access for hemodialysis, but can become a life-threatening emergency. Clinical features of SVC syndrome can be subtle or dramatic, including facial swelling and shortness of breath, which require expeditious attention and intervention. The approach to SVC syndrome involves judicious use of imaging techniques to define the cause and location. Early management with endovascular intervention with angioplasty and stent placement is the usual first choice. The occlusion can often be recanalized using new techniques such as radiofrequency wire and then salvaged with stents, providing prompt resolution of symptoms. Limitations to interventions include requirement of cutting-edge equipment, expertise, expense, and the usually temporary nature of the resolution. Surgery is considered the treatment of last resort for refractory cases. SVC syndrome can be prevented by minimizing catheter and intravascular device use through early recognition of patients with chronic kidney disease, early referral for education about all choices for kidney replacement modalities, and early placement of arteriovenous access prior to the onset of dialysis therapy.
                Bookmark

                Author and article information

                Contributors
                Journal
                Hematol Transfus Cell Ther
                Hematol Transfus Cell Ther
                Hematology, Transfusion and Cell Therapy
                Sociedade Brasileira de Hematologia e Hemoterapia
                2531-1379
                2531-1387
                17 February 2018
                Jan-Mar 2018
                17 February 2018
                : 40
                : 1
                : 75-78
                Affiliations
                [0005]Babol University of Medical Sciences, Babol, Iran
                Author notes
                [* ] Corresponding author at: Department of Hematology and Medical Oncology, Clinical Research Development Unit of Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran. mvakili89@ 123456gmail.com
                Article
                S2531-1379(18)30002-6
                10.1016/j.htct.2017.09.001
                6001923
                69c2c043-b478-4bfb-b351-e88104290de4
                © 2018 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 3 May 2017
                : 11 September 2017
                Categories
                Case Report

                Comments

                Comment on this article